title: Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling.
abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Despite a high level of interest in MPO as a therapeutic target, there have been limited reports about MPO inhibitors that are suitable for evaluating MPO in pharmacological studies. 2-Thioxanthine, 3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one (A), has recently been reported to inhibit MPO by covalently modifying the heme prosthetic group. Here we report a detailed mechanistic characterization demonstrating that A possesses all the distinguishing features of a mechanism-based inactivator. A is a time-dependent MPO inhibitor and displays saturable inactivation kinetics consistent with a two-step mechanism of inactivation and a potency (k(inact)/K(I) ratio) of 8450 ± 780 M⁻¹ s⁻¹. MPO inactivation by A is dependent on MPO catalysis and is protected by substrate. A reduces MPO compound I to compound II with a second-order rate constant of (0.801 ± 0.056) × 10⁶ M⁻¹ s⁻¹, and its irreversible inactivation of MPO occurs prior to release of the activated inhibitory species. Despite its relatively high selectivity against a broad panel of more than 100 individual targets, including enzymes, receptors, transporters, and ion channels, we demonstrate that A labels multiple other protein targets in the presence of MPO. By synthesizing an alkyne analogue of A and utilizing click chemistry-activity-based protein profiling, we present that the MPO-activated inhibitory species can diffuse away to covalently modify other proteins, as reflected by the relatively high partition ratio of A, which we determined to be 15.6. This study highlights critical methods that can guide the discovery and development of next-generation MPO inhibitors.
authors: Cardiovascular and Metabolic Diseases Research Unit and ‡Medicinal Chemistry, Pfizer Worldwide Research and Development , Cambridge, Massachusetts 02139, United States.
authors: Jessica
authors: J
authors: Ward
authors: Samantha N
authors: SN
authors: Spath
authors: Brandon
authors: B
authors: Pabst
authors: Philip A
authors: PA
authors: Carpino
authors: Roger B
authors: RB
authors: Ruggeri
authors: Gang
authors: G
authors: Xing
authors: Anna E
authors: AE
authors: Speers
authors: Benjamin F
authors: BF
authors: Cravatt
authors: Kay
authors: K
authors: Ahn
mesh_terms: D000480:Alkynes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D001667:Binding, Competitive; D055162:Biocatalysis; D057930:Click Chemistry; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D010078:Oxazines / Q000378:metabolism; D009195:Peroxidase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D011355:Prodrugs / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D020543:Proteome / Q000737:chemistry; D012995:Solubility; D013871:Thiones / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D014970:Xanthines / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*
chemical_list: C586749:3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one; D000480:Alkynes; D004791:Enzyme Inhibitors; D010078:Oxazines; D011355:Prodrugs; D020543:Proteome; D013871:Thiones; D014970:Xanthines; C470430:Amplex Red; D006861:Hydrogen Peroxide; D009195:Peroxidase